Skip to content

PolitiKit

Alan Walshe's lobbying: the registrations they file and every meeting they've reported since November 2021.

← Lobbying

Registrant (responsible officer)

Alan Walshe

General Manager, Takeda Canada Inc.

For companies and organizations, the most senior paid officer files the registration and the monthly reports, whoever attended the meeting.

Meetings this Parliament
6
Since Nov 2021
6
Active registrations
1

Reported meetings

  • Takeda Canada Inc.
    • Kaili Levesque · Associate Deputy Minister, Fisheries and Oceans Canada (DFO)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 6 more
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health, Health Canada (HC)
    • Linsey Hollett · ADM, Health Canada (HC)
    Engagement on international trade discussions and policies that may impact access to medicines and the security of drug supply in Canada.

    Official report

  • Takeda Canada Inc.
    • Anie Perrault · Chairperson, Patented Medicine Prices Review Board (PMPRB)
    Pharmaceutical pricing policy considerations within the mandate of the Patented Medicine Prices Review Board (PMPRB), including regulatory amendments and associated guidance. Read more

    Official report

  • Takeda Canada Inc.
    • Arianne Reza · Deputy Minister, Public Services and Procurement Canada (PSPC)
    • Joelle Paquette · Acting Associate Deputy Minister, Public Health Agency of Canada (PHAC)
    Engagement on international trade discussions and policies that may impact access to medicines and the security of drug supply in Canada.

    Official report

  • Takeda Canada Inc.
    Engagement on international trade discussions and policies that may impact access to medicines and the security of drug supply in Canada.

    Official report

  • Takeda Canada Inc.
    Engagement on federal policies and programmes related to the availability, appropriate use, and continuity of supply of plasma?derived therapies, including immunoglobulins, for patients with immune?mediated and rare conditions. Read more

    Official report

  • Takeda Canada Inc.
    • Maggie Chi · Member of Parliament
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Elizabeth Wong · Senior Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    and 7 more
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health, Health Canada (HC)
    Engagement on international trade discussions and policies that may impact access to medicines and the security of drug supply in Canada. Read more

    Pharmaceutical pricing policy considerations within the mandate of the Patented Medicine Prices Review Board (PMPRB), including regulatory amendments and associated guidance.

    Canada’s Drug Agency policy frameworks and processes related to reimbursement recommendations, including decision?making approaches and timelines.

    Engagement on federal policies and frameworks that support improved coordination across jurisdictions to facilitate timely patient access following Health Canada approval.

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.